■这项研究的目的是评估burosumab治疗X连锁低磷血症(XLH)儿童的有效性。
■我们系统地回顾了PubMed的文献,WebofScience,科克伦图书馆,和Embase直到2024年1月,使用EndNoteWeb进行学习组织。纽卡斯尔-渥太华量表指导质量评估,而Revman软件用于数据分析和可视化。研究选择,质量评价,数据汇总由三名研究人员独立进行。
■荟萃分析涵盖了十项研究,包括八项队列研究,检查burosumab的影响前和后的管理,和两项比较burosumab和标准疗法的随机对照试验。本综述的证据表明burosumab在儿科人群中管理XLH方面具有优势,特别是在改善关键生化指标,包括1,25-二羟基维生素D(1,25-(OH)2D),磷,和碱性磷酸酶(ALP),除了改善肾小管最大磷酸盐重吸收速率对肾小球滤过率(TmP/GFR)外,并显着的骨骼改善,如病严重程度评分(RSS)和6分钟步行测试(6MWT)所示。然而,长期的安全性和效果,包括身高和生活质量(QOL)数据,还有待阐明。
■Burosumab在治疗XLH儿童方面显示出显着的治疗效果,强调其作为关键治疗选择的潜力。
UNASSIGNED: The aim of this study was to evaluate the effectiveness of burosumab therapy in children with X-Linked Hypophosphatemia (XLH).
UNASSIGNED: We systematically reviewed literature from PubMed, Web of Science, The Cochrane Library, and Embase up until January 2024, using EndNote Web for study organization. The Newcastle-Ottawa scale guided quality assessment, while Revman software was used for data analysis and visualization. Study selection, quality evaluation, and data aggregation were independently performed by three researchers.
UNASSIGNED: The meta-analysis encompassed ten studies, including eight cohort studies that examined burosumab\'s impact pre- and post-administration, and two randomized controlled trials comparing burosumab to standard therapy. The evidence from this
review suggests burosumab\'s superiority in managing XLH in pediatric populations, particularly in improving key biochemical markers including 1,25-dihydroxyvitamin D (1,25-(OH)2D), phosphorus, and alkaline phosphatase (ALP), alongside improvements in the renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR), and significant skeletal improvements as indicated by the rickets severity score (RSS) and the 6-minute walk test (6MWT). However, the long-term safety and effects, including height and quality of life (QOL) data, remains to be elucidated.
UNASSIGNED: Burosumab has shown significant therapeutic effectiveness in treating children with XLH, highlighting its potential as a key treatment option.